Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Viewpoint

Vol. 154 No. 8 (2024)

It has been 30 years since the first alcohol septal ablation for hypertrophic obstructive cardiomyopathy was performed

DOI
https://doi.org/10.57187/s.3891
Cite this as:
Swiss Med Wkly. 2024;154:3891
Published
16.08.2024

Summary

No abstract available.

References

  1. Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet. 2017 Mar;389(10075):1253–67. 10.1016/S0140-6736(16)31321-6 DOI: https://doi.org/10.1016/S0140-6736(16)31321-6
  2. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guideline. Circulation. 2020 Dec;142(25):e533–57. DOI: https://doi.org/10.1161/CIR.0000000000000938
  3. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct;44(37):3503–626. 10.1093/eurheartj/ehad194
  4. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995 Jul;346(8969):211–4. 10.1016/S0140-6736(95)91267-3 DOI: https://doi.org/10.1016/S0140-6736(95)91267-3
  5. Goodwin JF, Oakley CM, Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995 Dec;346(8990):1624. 10.1016/S0140-6736(95)91954-6 DOI: https://doi.org/10.1016/S0140-6736(95)91954-6
  6. ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail. 2010 May;3(3):362–9. 10.1161/CIRCHEARTFAILURE.109.862359 DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.109.862359
  7. Veselka J, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016 May;37(19):1517–23. 10.1093/eurheartj/ehv693 DOI: https://doi.org/10.1093/eurheartj/ehv693
  8. Veselka J, Tesař D, Topalo R, Hansvenclová E, Adlová R. Follow-up of up to 25 years after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2023 Jun;16(12):1556–7. 10.1016/j.jcin.2023.03.049 DOI: https://doi.org/10.1016/j.jcin.2023.03.049
  9. Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022 Jul;80(2):95–108. 10.1016/j.jacc.2022.04.048 DOI: https://doi.org/10.1016/j.jacc.2022.04.048